Related Experiment Video
Updated: Oct 9, 2025

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
Published on: July 5, 2017
Raspberry (Rubus idaeus L.), a Promising Alternative in the Treatment of Hyperglycemia and Dyslipidemias
Norma Piña-Contreras1, Alma Gabriela Martínez-Moreno1, Jessica Del Pilar Ramírez-Anaya2
1Behavioral Feeding and Nutrition Research Institute (IICAN), South University Center, University of Guadalajara, Ciudad Guzmán, Jalisco, Mexico.
Abstract:
Raspberry production and consumption have increased in recent years due to its polyphenol content such as anthocyanins and ketones, bioactive compounds that have been studied to reduce blood glucose levels and stabilize the blood lipid profile. The objective of this study was to systematically recover and review scientific evidence regarding the consumption of raspberry or its bioactive compounds and the action mechanisms involved in the hypoglycemic and lipid-lowering effects they present. Original articles from in vitro and in vivo enzyme inhibition studies, animal models, and human clinical studies were compiled in PubMed, Web of Science, and Science Direct databases. Studies showed satisfactory results regarding blood glucose level reduction after consumption of frozen or lyophilized raspberry, infusion of raspberry leaves, seed oil, as well as compounds, extracted from the fruit by inhibiting enzymes such as α-glucosidase and dipeptidyl peptidase-4 (DPP-4) and other mechanisms that increase insulin production and insulin sensitivity. However, regarding the lipid-lowering effect, the results were heterogeneous, mainly in terms of stabilization in triglyceride levels. However, a reduction in cholesterol and low-density lipoprotein levels is reported, as well as an increase in high-density lipoproteins. According to the results, raspberry can be included in the nonpharmacological treatment of hyperglycemia and dyslipidemias; however, further research is considered necessary.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Hypoglycemia and Glucagon

